Healthcare Most Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Johnson & Johnson (NYSE:JNJ)

A proxy advisory firm has asked shareholders of the Indian unit of Wyeth to oppose its merger deal with Pfizer Inc. (NYSE:PFE) as the share swap ratio is skewed in favour of Pfizer Inc. (NYSE:PFE). Shareholder Empowerment Services (SES) has made this suggestion ahead of the shareholder meeting this week. Pfizer Inc. (NYSE:PFE) stock performance was 0.07% in last session and finished the day at … Continue reading Healthcare Most Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Johnson & Johnson (NYSE:JNJ)

Healthcare Active Runners: Gilead Sciences (NASDAQ:GILD), Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), MannKind Corporation (NASDAQ:MNKD)

Gilead Sciences, Inc. (NASDAQ:GILD) announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi(R) (sofosbuvir) 400 mg was administered for the treatment of chronic hepatitis C virus (HCV) infection in patients with advanced liver disease. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was -7.32% in last session and finished the day at $65.48. Traded volume was 43.15million … Continue reading Healthcare Active Runners: Gilead Sciences (NASDAQ:GILD), Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), MannKind Corporation (NASDAQ:MNKD)

During the trial, palbociclib — a pill — was combined with the standard anti-estrogen treatment Letrozole. The combined treatment resulted in a 26.1 month progression-free survival rate compared with only 7.5 months for Letrozole alone. Under development by Pfizer Inc. (NYSE:PFE), the medication used in the study is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Pfizer Inc. (NYSE:PFE) stock performance was -1.06% … Continue reading Healthcare Most Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Teva Pharmaceutical Industries (NYSE:TEVA), Bristol-Myers Squibb (NYSE:BMY)

On Monday, Johnson & Johnson (NYSE:JNJ) announced that it accepted the binding offer from The Carlyle Group (NASDAQ:CG), which was received and announced on January 16, 2014, to acquire its Ortho-Clinical Diagnostics business for approximately $4 Billion, subject to customary adjustments. Johnson & Johnson (NYSE:JNJ) stock performance was 0.16% in last session and finished the day at $98.42. Traded volume was 10.31million shares in the … Continue reading Healthcare active runners: Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer Inc. (NYSE:PFE), MannKind Corporation (NASDAQ:MNKD)

Three years after Pfizer Inc. (NYSE:PFE) dropped a bombshell on its plans to lay off more than 1000 workers. The biopharmaceutical company has come back with some of the best news, on how it plans to use the vacated Groton site. In a joint announcement, Gov. Dannel P. Malloy and Pfizer confirmed that two buildings on the company’s campus will be donated for use in … Continue reading DRug Active runners: Pfizer Inc. (NYSE:PFE), Sanofi SA (ADR) (NYSE:SNY), AbbVie Inc (NYSE:ABBV), Johnson & Johnson (NYSE:JNJ)

Three years after Pfizer Inc. (NYSE:PFE) announced more than 1,000 layoffs that Gov. Dannel P. Malloy at the time called “terrible news,” the pharmaceutical company and the state said Wednesday they’ve come up with new uses for the Groton site. Malloy and top officials of his administration and Pfizer Inc (NYSE:PFE) said two vacant buildings on the company’s campus will be used for bioscience research … Continue reading Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb (NYSE:BMY)